Form 4: Monopar CFO Acquires Stock Options and RSUs

Monopar Therapeutics' Chief Financial Officer, Quan Anh Vu, acquired 7,135 stock options and 9,826 restricted stock units on December 2, 2025.

Summary

• Quan Anh Vu, Chief Financial Officer of Monopar Therapeutics [MNPR], reported the acquisition of derivative securities.
• Acquired 7,135 stock options with an exercise price of $75.94 per share.
• Acquired 9,826 Restricted Stock Units (RSUs).
• The transaction date for both acquisitions was December 2, 2025.
• The stock options begin vesting 6/48ths on June 30, 2026, and 1/48th per month thereafter, with an expiration date of December 2, 2035.
• The RSUs begin vesting 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter.

Sentiment

Score: 6

Explanation: The acquisition of equity by a key executive is generally a positive signal, indicating confidence in the company's future. However, this is a routine compensation disclosure and not indicative of extraordinary performance or strategic shifts.

Positives

• CFO Quan Anh Vu's acquisition of 7,135 stock options and 9,826 Restricted Stock Units aligns management's long-term interests with those of shareholders.

Future Outlook

This filing does not contain forward-looking statements or guidance beyond the vesting schedules of the granted equity awards.

Industry Context

The grant of stock options and restricted stock units to a Chief Financial Officer is a standard practice in executive compensation within the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The equity grants to the CFO are intended to align management's financial interests with shareholder returns, potentially fostering long-term value creation.

Next Steps

• Continued vesting of the granted stock options and Restricted Stock Units according to their respective schedules.

Key Dates

Recommendation

This Form 4 reports a routine grant of equity compensation to a key executive. While insider ownership can be a positive signal, this filing alone does not provide sufficient fundamental or strategic information to warrant a change in investment recommendation. Investors should consider broader company performance, financial results, and market conditions.

Keywords

Monopar Therapeutics, MNPR, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Executive Compensation, CFO